Long-Term Effectiveness and Durability of COVID-19 Vaccination among Patients with Inflammatory Bowel Disease

COVID-19 vaccination prevents severe disease in most patients with IBD, but immunosuppressive medications can blunt serologic response. We followed adults with IBD for>1-year post-COVID-19 vaccination to describe factors associated with SARS-CoV-2 infection after vaccination, evaluate for a protective SARS-CoV-2 antibody level, characterize SARS-CoV-2 antibody persistence, and identify factors associated with humoral immune response durability.

Source: Clinical Gastroenterology and Hepatology - February 16, 2024 Category: Gastroenterology Authors: Erica J. Brenner, Kimberly N. Weaver, Xian Zhang, Arthur J. Kastl, Jennifer A. Strople, Jeremy Adler, Marla C. Dubinsky, Athos Bousvaros, Runa Watkins, Xiangfeng Dai, Wenli Chen, Raymond K. Cross, Peter D.R. Higgins, Ryan C. Ungaro, Meenakshi Bewtra, Eman Source Type: research